Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
2016
|
| Rochtain ar líne: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|
Bí ar an gcéad duine le trácht a dhéanamh!